Delivery Order SPE2DB22D3010-SPE2DB25FP3KV
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) with a ceiling value of $18,978.90. This non-set-aside competitive award is scheduled for completion by August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,515.37 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages). This competitively awarded, firm fixed-price contract was issued on July 29, 2025, with an ultimate completion date of July 30, 2025. The order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen Drug...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $9,023.70 on August 8, 2025, for the supply of Eliquis 5 mg tablets (60-count packages). This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor. The delivery order is scheduled for completion by August 11, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,308.26 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages). This competitively awarded, firm fixed price delivery order was issued on August 20, 2025, with an ultimate completion date of August 21, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the open competitive procurement process....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) under a firm fixed-price contract valued at $105,321.66. The order, issued on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) valued at $16,636.35 under a firm fixed-price contract. The award was made on August 25, 2025, with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the delivery of this pharmaceutical product from its corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,931.20 to AmerisourceBergen Drug Corp for the supply of Eliquis 2.5 mg tablets (60-count units) on August 19, 2025, with completion scheduled for August 20, 2025. This firm fixed-price delivery order carries no set-aside designation and was competitively awarded under an existing Indefinite Delivery Contract (IDC). The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,827.12 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) under a firm fixed-price contract. The delivery order was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, and represents a non-competitive, competitively awarded transaction. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,097.62 to AmerisourceBergen Drug Corp for Eliquis 5 mg tablets (60-count) on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order represents a non-competitive award under the DLA's pharmaceutical supply framework and was fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract is classified as a child order, indicating it...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 2.5 mg tablets (60-count packages) with a ceiling value of $4,039.17. This is a firm fixed-price delivery order with an ultimate completion date of August 20, 2025, issued on August 19, 2025. The contract is non-set-aside and was competitively awarded. AmerisourceBergen's place of performance is listed as its corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP3KVDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,315.49 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count package) with a firm fixed price structure. The contract, which was competitively awarded with no set-aside designation, is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery order has an ultimate completion date of September 10, 2025, with performance to be fulfilled at AmerisourceBergen's corporate facility in Conshohocken, Pennsylvania. This delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier within the federal medical procurement system. The company holds a significant prime IDC valued at $999,999,999.00 with DLA that extends through December 2026, enabling the supply of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Eliquis, an anticoagulant medication, supports the DLA's mandate to maintain adequate pharmaceutical inventory for military medical readiness and patient care across the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.3k | 9/9/25 |